SMN2 and spinal muscular atrophy, type 1: The FIREFISH trial (Part 2) enrolled 41 infants with SMA type I, aged 1 to 7 months at enrolment, with a genetically confirmed diagnosis of SMA and two SMN2 gene copies [153].